Sutro Biopharma (STRO) Common Equity (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Common Equity data on file, last reported at -$132.5 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 396.97% year-over-year to -$132.5 million; the trailing twelve-month figure through Dec 2025 stood at -$132.5 million (down 396.97% YoY), and the FY2025 full-year result was -$132.5 million, down 396.97% from the prior year.
• Common Equity eased to -$132.5 million in Q4 2025, from -$87.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $307.5 million in Q2 2021 to a low of -$132.5 million in Q4 2025.
• A 5-year average of $137.9 million and a median of $153.4 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 274.41% in 2021 and plunged 396.97% in 2025, its largest moves.
• Tracing STRO's Common Equity over 5 years: stood at $252.6 million in 2021, then dropped by 14.06% to $217.0 million in 2022, then plunged by 31.05% to $149.6 million in 2023, then tumbled by 70.2% to $44.6 million in 2024, then plunged by 396.97% to -$132.5 million in 2025.
• Business Quant data shows STRO's Common Equity at -$132.5 million in Q4 2025, -$87.3 million in Q3 2025, and -$32.1 million in Q2 2025.